Transendothelial Transport of Low-Density Lipoproteins in Atherosclerosis: Mechanisms of Activation and Possible Therapeutic Targets
- 1Department of Biological and Medical Chemistry, Institute of Experimental Medicine, 12, Acad. Pavlov Street, St. Petersburg 197022, Russia
Abstract
Despite advances in the prevention of cardiovascular events in recent decades, the risk of developing atherosclerosis and its complications remains a major challenge. One promising way to reduce this risk is to develop measures to inhibit the activated transport of low-density lipoproteins (LDLs) through the endothelium, which is the initial stage of atherosclerosis. Recent research has provided some molecular details of the mechanism, including the roles of caveolin-1, LDL receptors, and certain motor proteins. This review summarizes data on recent advances in studying of LDL endothelial transcytosis, focusing on its role in atherogenesis as well as on its regulation by hemodynamics, lipoproteins, cytokines, and metabolic factors. Data on potential targets for inhibiting transendothelial LDL transport are also presented. A better understanding of the mechanisms of endothelial LDL transcytosis and the development of drugs to inhibit it may lead to improved treatment of atherosclerosis and more effective prevention of cardiovascular events.
Related
- Multifaceted Physiological Roles of Lipoproteins and Understanding Atherosclerosis: Crosstalk Between Lipoproteins and Bioactive Lipids
- Role of insulin resistance in atherosclerosis: underlying mechanisms and emerging stem cell-based therapeutic strategies.
- Posttranslational Modification Cross-Talk in Vascular Cells: Molecular Mechanisms and Therapeutic Implications for Atherosclerosis.
- Selenium Nanoparticles in Atherosclerosis and Non-Alcoholic Fatty Liver Disease: A Comprehensive Review of Therapeutic Mechanisms, Targeted Delivery, and Translational Prospects
- PCSK9 as a mediator of monocytes transendothelial activation in obstructive sleep apnoea: A translational study
BibTeX
@article{tanyanskiy2026transendothelial,
title = {{Transendothelial Transport of Low-Density Lipoproteins in Atherosclerosis: Mechanisms of Activation and Possible Therapeutic Targets}},
author = {Dmitry Tanyanskiy and Alexander Denisenko},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219492},
url = {https://www.mdpi.com/1422-0067/27/21/9492},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Transendothelial Transport of Low-Density Lipoproteins in Atherosclerosis: Mechanisms of Activation and Possible Therapeutic Targets
AU - Dmitry Tanyanskiy
AU - Alexander Denisenko
PY - 2026
DA - 2026/10/24
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219492
UR - https://www.mdpi.com/1422-0067/27/21/9492
AB - Despite advances in the prevention of cardiovascular events in recent decades, the risk of developing atherosclerosis and its complications remains a major challenge. One promising way to reduce this risk is to develop measures to inhibit the activated transport of low-density lipoproteins (LDLs) through the endothelium, which is the initial stage of atherosclerosis. Recent research has provided some molecular details of the mechanism, including the roles of caveolin-1, LDL receptors, and certain motor proteins. This review summarizes data on recent advances in studying of LDL endothelial transcytosis, focusing on its role in atherogenesis as well as on its regulation by hemodynamics, lipoproteins, cytokines, and metabolic factors. Data on potential targets for inhibiting transendothelial LDL transport are also presented. A better understanding of the mechanisms of endothelial LDL transcytosis and the development of drugs to inhibit it may lead to improved treatment of atherosclerosis and more effective prevention of cardiovascular events.
SN - 1422-0067
ER -